Tyra Biosciences (TYRA) Set to Announce Quarterly Earnings on Wednesday

Key Points

• Tyra Biosciences is expected to report Q3 2026 earnings after the market closes on November 4, with analysts forecasting a loss of $0.6687 per share. The company previously reported a $0.69-per-share loss, missing estimates by $0.04.
• TYRA shares opened at $21.52, with the stock trading between a 52-week range of $13.35 to $40.65 and a market capitalization of approximately $1.28 billion.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $47.20, although ratings range from “Strong Buy” to “Sell.” Tyra’s lead drug candidate, TYRA-300, is being tested as a selective FGFR3 inhibitor for cancer indications.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.6687) per share for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, analysts expect Tyra Biosciences to post ($2.68) EPS for the current fiscal year and ($2.76) EPS for the next fiscal year.

Tyra Biosciences Stock Up 5.4%

TYRA opened at $21.52 on Wednesday. Tyra Biosciences has a fifty-two week low of $13.35 and a fifty-two week high of $40.65. The firm has a market cap of $1.28 billion, a PE ratio of -8.97 and a beta of 0.75. The business has a fifty day simple moving average of $22.96 and a 200-day simple moving average of $29.94.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on TYRA shares. Wedbush reiterated an "outperform" rating and set a $53.00 price target on shares of Tyra Biosciences in a research note on Thursday, September 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Tyra Biosciences in a research report on Thursday, October 15th. William Blair raised shares of Tyra Biosciences to a "strong-buy" rating in a report on Wednesday, September 23rd. Cantor Fitzgerald restated an "overweight" rating on shares of Tyra Biosciences in a research report on Thursday, September 10th. Finally, Piper Sandler reissued an "overweight" rating and set a $56.00 price target on shares of Tyra Biosciences in a research note on Tuesday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $47.20.

About Tyra Biosciences

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for patients with cancer and other diseases driven by fibroblast growth factor receptor (FGFR) abnormalities. The company uses its proprietary SNÅP platform to discover and design small-molecule therapies intended to selectively target FGFR alterations while addressing mechanisms of treatment resistance.

Tyra's lead program, TYRA-300, is an oral, selective FGFR3 inhibitor being evaluated in clinical studies for FGFR3-altered urothelial cancer and other potential indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.